Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nichi-Iko Pharmaceutical Co stock price, quote, forecast and news

4541.T
JP3687200000
A0DQVE

Price

35.00
Today +/-
+0
Today %
+0 %
P

Nichi-Iko Pharmaceutical Co stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Nichi-Iko Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nichi-Iko Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nichi-Iko Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nichi-Iko Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nichi-Iko Pharmaceutical Co Stock Price History

DateNichi-Iko Pharmaceutical Co Price
3/28/202335.00 undefined
3/27/202335.00 undefined

Nichi-Iko Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Nichi-Iko Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nichi-Iko Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nichi-Iko Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nichi-Iko Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nichi-Iko Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nichi-Iko Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nichi-Iko Pharmaceutical Co’s growth potential.

Nichi-Iko Pharmaceutical Co Revenue, EBIT and net profit per share

DateNichi-Iko Pharmaceutical Co RevenueNichi-Iko Pharmaceutical Co EBITNichi-Iko Pharmaceutical Co Net Income
2027e225.13 B undefined0 undefined-156.5 B undefined
2026e222.35 B undefined0 undefined-96.34 B undefined
2025e217.76 B undefined0 undefined-59.9 B undefined
2024e201.8 B undefined0 undefined-109.65 B undefined
2023e192.91 B undefined0 undefined-535.14 B undefined
2022179.06 B undefined-28.29 B undefined-104.98 B undefined
2021188.22 B undefined1.86 B undefined-4.18 B undefined
2020190.08 B undefined6.86 B undefined5.13 B undefined
2019166.59 B undefined7.41 B undefined6.86 B undefined
2018164.72 B undefined13.27 B undefined8.07 B undefined
2017149.26 B undefined6.8 B undefined4.8 B undefined
2016143.51 B undefined12.67 B undefined11.03 B undefined
2015127.02 B undefined9.62 B undefined6.59 B undefined
2014103.62 B undefined7.38 B undefined4.59 B undefined
201393.93 B undefined8.23 B undefined5.13 B undefined
201227 B undefined2.15 B undefined1.33 B undefined
201177.74 B undefined7.51 B undefined3.91 B undefined
201064.35 B undefined7.22 B undefined3.87 B undefined
200954.81 B undefined6.09 B undefined3.76 B undefined
200842.84 B undefined5.41 B undefined3.44 B undefined
200732.33 B undefined4.34 B undefined2.62 B undefined
200629.25 B undefined3.85 B undefined2.41 B undefined
200524.3 B undefined2.43 B undefined1.24 B undefined
200418.3 B undefined2.56 B undefined143 M undefined
200317.65 B undefined2.7 B undefined2.36 B undefined

Nichi-Iko Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e
9.9211.0611.4812.5114.6617.6518.324.329.2532.3342.8454.8164.3577.742793.93103.62127.02143.51149.26164.72166.59190.08188.22179.06192.91201.8217.76222.35225.13
-11.503.758.9717.2320.363.6832.8120.3910.5132.5227.9317.4220.80-65.27247.8910.3222.5812.984.0110.351.1414.10-0.98-4.877.734.617.912.111.25
21.5939.1739.8143.8844.8549.1548.3746.9147.0848.2646.8644.4642.5840.2837.2539.0438.2937.0737.2925.2024.7719.9019.6311.292.21-----
2.144.334.575.496.588.678.8511.413.7715.620.0824.3727.431.3210.0636.6739.6847.0953.5137.6140.833.1637.3221.253.9700000
-1.440.660.650.961.652.72.562.433.854.345.416.097.227.512.158.237.389.6212.676.813.277.416.861.86-28.2900000
-14.505.985.627.6811.2315.3114.0110.0013.1713.4212.6211.1211.229.667.958.777.127.578.834.568.064.453.610.99-15.80-----
-3.890.620.250.921.162.360.141.242.412.623.443.763.873.911.335.134.596.5911.034.88.076.865.13-4.18-104.98-535.14-109.65-59.9-96.34-156.5
--116.03-59.94266.8026.17103.98-93.94768.5393.728.7731.529.332.741.09-65.94285.42-10.5743.6867.34-56.5268.24-14.93-25.22-181.412,412.18409.73-79.51-45.3760.8362.44
383838383837363637404040415052514459.8659.9557.0356.4660.1964.0664.0267.5400000
------------------------------
Details

Keystats

Revenue and Growth

The Nichi-Iko Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nichi-Iko Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                 
2.111.741.990.960.91.321.040.744.060.751.071.551.74.136.35.3121.714.0328.1812.8219.542.5443.3732.8615.73
3.523.713.793.694.645.817.549.811.1310.7316.8913.9918.2224.2223.4126.3127.7921.1624.4130.9628.9928.4538.5236.4234.49
00000000000000000001.743.11.651.46.524.11
2.252.1822.53.113.453.444.866.328.3213.216.1317.6620.2922.5828.1332.6542.4345.3467.9674.3266.7878.1396.1195.75
0.420.230.230.510.860.691.270.770.980.951.622.212.011.911.692.611.432.183.72.082.373.293.293.25.31
8.297.868.017.679.511.2813.2916.1722.4920.7432.7833.8739.5950.5553.9862.3683.5779.8101.62115.56128.28142.72164.71175.1155.39
6.686.1210.7710.3110.1410.25.538.859.8710.1113.3917.7418.8121.0523.3230.4129.7534.1138.7947.4254.0555.7159.268.9439.29
0.510.510.480.590.780.850.91.611.461.321.141.462.374.114.324.28.5713.68.712.4310.3418.729.9913.847.53
0.260.230.60.560.590.120.090.050.040.080.080.080.330.70.760.741.9300000000
0.020.040.050.110.120.150.130.090.10.071.592.272.714.393.932.862.283.585.8550.1345.7446.7256.6156.9639.61
00000000000.9610.940.81.151.511.291.080.6340.4938.5442.8944.3245.6618.48
0.970.940.060.210.430.740.560.750.720.831.041.050.841.191.010.841.751.30.922.881.430.081.993.070.26
8.447.8411.9511.7812.0612.067.211.3412.212.4118.223.5925.9932.2434.4840.5645.5653.6654.89153.34150.09164.12172.11188.47105.17
16.7315.719.9619.4521.5623.3320.527.5134.6833.1550.9857.4765.5882.7988.46102.92129.13133.46156.51268.9278.36306.84336.82363.57260.56
                                                 
1.461.461.461.461.461.461.461.461.463.063.063.065.2713.5613.5613.5619.9819.9819.9819.9819.9823.3623.3623.3625.98
3.540000000.050.051.691.841.844.0512.3412.3212.2718.6818.6818.818.8518.8321.921.921.924.51
-3.750.41-0.390.461.543.83.784.8779.311.1214.0216.9619.6720.3624.4728.1433.3442.8545.0551.9155.0257.3750.82-55.66
00000000000000000.70.90.778.75.8718.9415.7717.3620.69
000-121-36245910-105-22631531321122339341145800000000
1.251.871.081.82.975.295.36.398.4113.8316.3419.2326.4945.7946.6350.7167.9572.982.3992.5796.59119.22118.39113.4315.52
2.11.942.012.312.963.143.214.695.876.1810.1311.5113.2513.3516.1622.322.9432.7630.1947.650.6944.1761.7565.3648.12
0.340.310.320.330.350.430.440.761.060.290.991.131.071.130.931.171.0301.8000000
0.490.470.440.580.750.881.351.471.731.783.224.042.994.443.267.576.429.6912.838.5711.2110.2314.1915.113.82
5.944.835.245.244.773.834.915.656.36.3213.2511.4312.455.425.854.0711.862.7514.7229.1228.5429.1737.6153.2960.88
1.582.032.312.012.411.120.981.471.250.340.891.621.882.863.33.774.484.94.728.086.968.269.139.8324.65
10.449.5810.3110.4611.249.410.914.0416.2114.9228.4829.7331.6327.1929.5138.8846.7250.164.2693.3697.3991.84122.69143.57147.47
4.233.377.356.015.57.253.913.886.971.362.95.474.577.449.8111.7112.599.3310.4678.6785.6390.7487.0586.0277.1
00000000.850.830.80.960.880.610.710.610.270.270.930.335.232.823.334.5214.7110.16
0.810.881.221.181.872.051.552.992.712.632.582.582.672.8633.263.363.473.478.474.984.615.396.8312.05
5.044.258.577.197.379.35.467.7310.514.796.438.937.851113.4215.2316.2113.7314.2792.3793.4398.6896.96107.5699.32
15.4813.8318.8817.6518.618.716.3521.7726.7219.7134.938.6639.4838.242.9354.1162.9463.8378.53185.73190.82190.52219.65251.14246.79
16.7315.719.9619.4521.5723.9921.6528.1635.1333.5451.2457.8965.9783.9989.56104.82130.88136.73160.92278.3287.41309.73338.04364.57262.3
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Nichi-Iko Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nichi-Iko Pharmaceutical Co's financial health and stability.

Assets

Nichi-Iko Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nichi-Iko Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nichi-Iko Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nichi-Iko Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0.260.440.592.440.062.123.424.015.015.475.876.592.38.177.069.4915.365.969.078.97.41.07-107.84
0.520.450.420.410.460.70.590.631.071.752.924.341.54.776.024.785.367.078.669.411.8713.2212.65
00000000000000000000000
-0.26-0.62-1.24-1.45-1.74-0.23-2.39-3.64-6.09-0.58-6.85-10.26-0.7-3.19-8.035.39-11.15-18.48-4.322.490.49-2.22-12.05
0.440.691.220.362.70.450.310.750.50.460.810.710.530.020.51.58-2.461.385.523.01-1.31-7.0682.99
41337534733928521516113019224525917744154150110133398608663671535725
0.010.010.010.010.130.071.091.730.722.472.452.041.971.73.611.653.836.640.482.441-0.12.68
0.960.950.981.751.483.031.941.740.487.092.751.373.639.775.5521.187.1-4.0818.9223.8118.455.01-24.25
-93-138-222-570-381-1,186-866-1,665-4,262-5,727-4,340-7,340-1,608-7,439-4,811-5,745-11,079-12,263-14,300-14,778-18,549-19,127-15,813
0.040.65-0.35-0.061.3-1.63-1.02-1.55-4.63-6.31-5.41-9.51-1.6-7.19-9.83-14.65-3.49-82.25-15.9-24.98-18.23-29.33-9.32
0.140.79-0.130.511.68-0.45-0.150.12-0.37-0.59-1.07-2.170.010.25-5.02-8.97.59-69.99-1.6-10.210.32-10.216.5
00000000000000000000000
-0.74-1.64-0.59-0.47-2.4-1.352.49-3.35.120.73-0.68-3.830.43-1.399-12.7912.0780.84.665.713.1813.0215.48
000-0.64-0.5-0.150.130.140.17-0.174.4315.670.08-0.8412.740.20.21-8.220.2410.870.230.25.28
-0.74-1.72-0.67-1.21-3.07-1.672.34-3.54.41-0.32.8310.65-0.13-3.320.68-14.1510.6370.733.2124.8110.8719.68
-0-0-0.01000000000000.2-0.09-0.010-09.96-0.49-0.44-0.44
0-73-75-99-168-165-281-339-885-863-924-1,196-633-1,070-1,269-1,469-1,647-1,853-1,686-1,734-1,915-1,918-644
0.26-0.12-0.040.48-0.29-0.273.26-3.30.260.480.162.511.91-0.7216.38-7.6614.14-15.696.0723.560.85-13.8-13.84
8698137611,1801,0971,8471,07179-3,7781,367-1,593-5,9682,0202,33273515,434-3,982-16,3394,6249,032-100-14,120-40,061
00000000000000000000000

Nichi-Iko Pharmaceutical Co stock margins

The Nichi-Iko Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nichi-Iko Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nichi-Iko Pharmaceutical Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nichi-Iko Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Nichi-Iko Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nichi-Iko Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nichi-Iko Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nichi-Iko Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nichi-Iko Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nichi-Iko Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nichi-Iko Pharmaceutical Co Margin History

Nichi-Iko Pharmaceutical Co Gross marginNichi-Iko Pharmaceutical Co Profit marginNichi-Iko Pharmaceutical Co EBIT marginNichi-Iko Pharmaceutical Co Profit margin
2027e2.21 %0 %-69.52 %
2026e2.21 %0 %-43.33 %
2025e2.21 %0 %-27.51 %
2024e2.21 %0 %-54.34 %
2023e2.21 %0 %-277.4 %
20222.21 %-15.8 %-58.63 %
202111.29 %0.99 %-2.22 %
202019.63 %3.61 %2.7 %
201919.9 %4.45 %4.12 %
201824.77 %8.06 %4.9 %
201725.2 %4.56 %3.21 %
201637.29 %8.83 %7.69 %
201537.07 %7.57 %5.19 %
201438.29 %7.12 %4.43 %
201339.04 %8.77 %5.46 %
201237.25 %7.95 %4.93 %
201140.28 %9.66 %5.03 %
201042.58 %11.22 %6.01 %
200944.46 %11.12 %6.87 %
200846.86 %12.62 %8.03 %
200748.26 %13.42 %8.1 %
200647.08 %13.17 %8.22 %
200546.91 %10 %5.11 %
200448.37 %14.01 %0.78 %
200349.15 %15.31 %13.37 %

Nichi-Iko Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Nichi-Iko Pharmaceutical Co earnings per share therefore indicates how much revenue Nichi-Iko Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Nichi-Iko Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nichi-Iko Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nichi-Iko Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nichi-Iko Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nichi-Iko Pharmaceutical Co Revenue, EBIT and net profit per share

DateNichi-Iko Pharmaceutical Co Sales per ShareNichi-Iko Pharmaceutical Co EBIT per shareNichi-Iko Pharmaceutical Co Earnings per Share
2027e319.82 undefined0 undefined-222.32 undefined
2026e315.86 undefined0 undefined-136.87 undefined
2025e309.34 undefined0 undefined-85.1 undefined
2024e286.67 undefined0 undefined-155.77 undefined
2023e274.05 undefined0 undefined-760.22 undefined
20222,651.12 undefined-418.83 undefined-1,554.37 undefined
20212,939.81 undefined29.1 undefined-65.27 undefined
20202,966.96 undefined107.14 undefined80.12 undefined
20192,767.62 undefined123.1 undefined114.03 undefined
20182,917.51 undefined235.08 undefined142.92 undefined
20172,617.39 undefined119.31 undefined84.1 undefined
20162,393.99 undefined211.34 undefined184.01 undefined
20152,122.01 undefined160.7 undefined110.13 undefined
20142,355.05 undefined167.8 undefined104.27 undefined
20131,841.69 undefined161.43 undefined100.59 undefined
2012519.21 undefined41.27 undefined25.6 undefined
20111,554.82 undefined150.22 undefined78.16 undefined
20101,569.59 undefined176.15 undefined94.29 undefined
20091,370.15 undefined152.3 undefined94.08 undefined
20081,071.03 undefined135.15 undefined86.05 undefined
2007808.2 undefined108.5 undefined65.43 undefined
2006790.65 undefined104.11 undefined65.03 undefined
2005674.97 undefined67.53 undefined34.5 undefined
2004508.22 undefined71.19 undefined3.97 undefined
2003476.95 undefined73 undefined63.78 undefined

Nichi-Iko Pharmaceutical Co business model

Nichi-Iko Pharmaceutical Co Ltd is a Japanese company founded in 1965 by Shin-ichi Oka. The company is now one of the largest generic drug manufacturers in Japan and has also made a name for itself in the international market in recent years. Nichi-Iko currently employs about 4800 people and is headquartered in Toyama, Japan. The business model of Nichi-Iko is focused on producing high-quality and cost-effective generic drugs for the global market. The company has an extensive research and development department that continuously develops and improves new products. The goal is to offer a wide range of medicines to meet the needs of patients in different countries. Nichi-Iko has various divisions that the company focuses on. One of the most important divisions is oncology products. Nichi-Iko has a wide range of products for cancer treatment on the market. The company has also expanded into other areas such as infectious diseases, cardiology, neurology, and dermatology. The product range includes tablets, capsules, injection solutions, eye drops, and inhalation products. The company also has an extensive distribution infrastructure that focuses on strengthening its global presence. Nichi-Iko has branches in Japan, the United States, Europe, and Asia. The presence in the global market has helped the company distribute its products in more than 50 countries. Nichi-Iko places a high value on quality control. The company has quality control facilities such as the central laboratory and research and development department. The company takes responsibility for the quality of its products and enables doctors and pharmacists to prescribe safe and effective medicines to their patients. Nichi-Iko also strives for a more sustainable future. The company is committed to promoting environmentally friendly business practices. Nichi-Iko is committed to reducing its energy and water consumption, as well as reducing its waste products. The company has also launched an initiative to promote medication recycling in order to expand the possibilities of using medical waste. In summary, Nichi-Iko Pharmaceutical Co Ltd is a leading generic drug manufacturer focused on producing high-quality and cost-effective medicines. The company has expanded into various areas and operates in the global market. Nichi-Iko places great importance on quality control and is committed to being more environmentally friendly. Nichi-Iko Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Nichi-Iko Pharmaceutical Co SWOT Analysis

Strengths

Nichi-Iko Pharmaceutical Co Ltd has several strengths that contribute to its competitive advantage in the pharmaceutical market. These strengths include:

  • Strong reputation and brand recognition in the industry
  • Extensive portfolio of high-quality and affordable generic pharmaceuticals
  • Robust research and development capabilities leading to innovative product offerings
  • Efficient supply chain management ensuring timely delivery of products
  • Established distribution network across domestic and international markets
  • Strategic partnerships and collaborations to enhance product development and market reach

Like any other company, Nichi-Iko Pharmaceutical Co Ltd has certain weaknesses that can hinder its growth and profitability. These weaknesses include:

  • Dependence on a limited number of key suppliers for raw materials
  • Susceptibility to changes in regulations and policies affecting the pharmaceutical industry
  • Relatively low presence in emerging markets
  • Limited diversification in therapeutic areas
  • Competitive pricing pressures in the generic pharmaceuticals segment
  • Operational challenges in integrating acquired companies

Nichi-Iko Pharmaceutical Co Ltd can take advantage of various opportunities to further expand its market presence and profitability. These opportunities include:

  • Increasing demand for generic pharmaceuticals worldwide
  • Expanding into new geographic markets with a focus on emerging economies
  • Investing in research and development to develop specialty pharmaceuticals
  • Strategic partnerships and acquisitions to enhance product portfolio and market access
  • Meeting the growing need for biosimilars and biopharmaceuticals
  • Utilizing digital technologies to improve operational efficiency and enhance customer experience

Nichi-Iko Pharmaceutical Co Ltd faces certain threats that pose challenges to its business operations and profitability. These threats include:

  • Intense competition from both generic and branded pharmaceutical manufacturers
  • Stringent regulatory requirements and increasing scrutiny on drug pricing
  • Potential disruptions in the global supply chain
  • Unpredictability of healthcare policies and reimbursement systems
  • Risks associated with product recalls and reputation damage
  • Rapidly evolving technological advancements in the pharmaceutical industry

Weaknesses

Like any other company, Nichi-Iko Pharmaceutical Co Ltd has certain weaknesses that can hinder its growth and profitability. These weaknesses include:

  • Dependence on a limited number of key suppliers for raw materials
  • Susceptibility to changes in regulations and policies affecting the pharmaceutical industry
  • Relatively low presence in emerging markets
  • Limited diversification in therapeutic areas
  • Competitive pricing pressures in the generic pharmaceuticals segment
  • Operational challenges in integrating acquired companies

Nichi-Iko Pharmaceutical Co Ltd can take advantage of various opportunities to further expand its market presence and profitability. These opportunities include:

  • Increasing demand for generic pharmaceuticals worldwide
  • Expanding into new geographic markets with a focus on emerging economies
  • Investing in research and development to develop specialty pharmaceuticals
  • Strategic partnerships and acquisitions to enhance product portfolio and market access
  • Meeting the growing need for biosimilars and biopharmaceuticals
  • Utilizing digital technologies to improve operational efficiency and enhance customer experience

Nichi-Iko Pharmaceutical Co Ltd faces certain threats that pose challenges to its business operations and profitability. These threats include:

  • Intense competition from both generic and branded pharmaceutical manufacturers
  • Stringent regulatory requirements and increasing scrutiny on drug pricing
  • Potential disruptions in the global supply chain
  • Unpredictability of healthcare policies and reimbursement systems
  • Risks associated with product recalls and reputation damage
  • Rapidly evolving technological advancements in the pharmaceutical industry

Opportunities

Nichi-Iko Pharmaceutical Co Ltd can take advantage of various opportunities to further expand its market presence and profitability. These opportunities include:

  • Increasing demand for generic pharmaceuticals worldwide
  • Expanding into new geographic markets with a focus on emerging economies
  • Investing in research and development to develop specialty pharmaceuticals
  • Strategic partnerships and acquisitions to enhance product portfolio and market access
  • Meeting the growing need for biosimilars and biopharmaceuticals
  • Utilizing digital technologies to improve operational efficiency and enhance customer experience

Nichi-Iko Pharmaceutical Co Ltd faces certain threats that pose challenges to its business operations and profitability. These threats include:

  • Intense competition from both generic and branded pharmaceutical manufacturers
  • Stringent regulatory requirements and increasing scrutiny on drug pricing
  • Potential disruptions in the global supply chain
  • Unpredictability of healthcare policies and reimbursement systems
  • Risks associated with product recalls and reputation damage
  • Rapidly evolving technological advancements in the pharmaceutical industry

Threats

Nichi-Iko Pharmaceutical Co Ltd faces certain threats that pose challenges to its business operations and profitability. These threats include:

  • Intense competition from both generic and branded pharmaceutical manufacturers
  • Stringent regulatory requirements and increasing scrutiny on drug pricing
  • Potential disruptions in the global supply chain
  • Unpredictability of healthcare policies and reimbursement systems
  • Risks associated with product recalls and reputation damage
  • Rapidly evolving technological advancements in the pharmaceutical industry

Nichi-Iko Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nichi-Iko Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Nichi-Iko Pharmaceutical Co shares outstanding

The number of shares was Nichi-Iko Pharmaceutical Co in 2023 — This indicates how many shares 67.541 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Nichi-Iko Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nichi-Iko Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nichi-Iko Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nichi-Iko Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nichi-Iko Pharmaceutical Co dividend history and estimates

In 2023, Nichi-Iko Pharmaceutical Co paid a dividend amounting to 0 JPY. Dividend means that Nichi-Iko Pharmaceutical Co distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Nichi-Iko Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Nichi-Iko Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Nichi-Iko Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Nichi-Iko Pharmaceutical Co Dividend History

DateNichi-Iko Pharmaceutical Co Dividend
202120 undefined
202030 undefined
201930 undefined
201830 undefined
201730 undefined
201618.4 undefined
201515.3 undefined
201424.6 undefined
201324.91 undefined
201220.78 undefined
201124.91 undefined
20101.56 undefined

Nichi-Iko Pharmaceutical Co dividend payout ratio

In 2023, Nichi-Iko Pharmaceutical Co had a payout ratio of 30.67%. The payout ratio indicates the percentage of the company's profits that Nichi-Iko Pharmaceutical Co distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Nichi-Iko Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Nichi-Iko Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Nichi-Iko Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Nichi-Iko Pharmaceutical Co Payout Ratio History

DateNichi-Iko Pharmaceutical Co Payout ratio
2027e31.17 %
2026e31.04 %
2025e30.34 %
2024e32.12 %
2023e30.67 %
202228.25 %
2021-30.64 %
202037.44 %
201926.31 %
201820.99 %
201735.67 %
201610 %
201513.89 %
201423.59 %
201324.76 %
201281.21 %
201131.87 %
20101.65 %
200928.25 %
200828.25 %
200728.25 %
200628.25 %
200528.25 %
200428.25 %
200328.25 %
Unfortunately, there are currently no price targets and forecasts available for Nichi-Iko Pharmaceutical Co.

Nichi-Iko Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/201810.3 43.6  (323.22 %)2019 Q1
6/30/201534.54 38.39  (11.14 %)2016 Q1
6/30/201424.54 32.01  (30.42 %)2015 Q1
3/31/201327.28 21.02  (-22.96 %)2013 Q4
12/31/201230.11 36.42  (20.96 %)2013 Q3
1

Nichi-Iko Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
89.98939 % Godo Kaisha JSD633,462,300633,462,3003/8/2023
0.99030 % Medipal Holdings Corp6,971,00009/30/2022
0.65220 % KK Tamura4,591,00015,0009/30/2022
0.40217 % The Hokuriku Bank, Ltd.2,831,00009/30/2022
0.30145 % Taku Co., Ltd.2,122,00009/30/2022
0.25429 % Tamura (Tomokazu)1,790,00009/30/2022
0.24190 % Nomura Asset Management Co., Ltd.1,702,782-2,2002/28/2023
0.17488 % Nichi-Iko Pharmaceutical Company Ltd. Employees1,231,00083,0009/30/2022
0.16085 % The Vanguard Group, Inc.1,132,279-204,4001/31/2023
0.16017 % Charles Schwab Investment Management, Inc.1,127,4898,5442/28/2023
1
2
3
4
5
...
8

Most common questions regarding Nichi-Iko Pharmaceutical Co

What values and corporate philosophy does Nichi-Iko Pharmaceutical Co represent?

Nichi-Iko Pharmaceutical Co Ltd represents a commitment to delivering high-quality pharmaceutical products and improving patient's lives. With a strong corporate philosophy focused on integrity, innovation, and patient-centeredness, Nichi-Iko aims to contribute to society by providing safe and effective medications. The company has a holistic approach towards healthcare, ensuring accessibility and affordability of their products. Nichi-Iko prioritizes customer satisfaction, continuous research and development, and collaborative partnerships to address the evolving medical needs of patients. Through their dedication to quality, Nichi-Iko Pharmaceutical Co Ltd strives to create a positive impact in the pharmaceutical industry and enhance the well-being of people worldwide.

In which countries and regions is Nichi-Iko Pharmaceutical Co primarily present?

Nichi-Iko Pharmaceutical Co Ltd is primarily present in Japan, where it is headquartered. As a prominent pharmaceutical company, Nichi-Iko focuses on the manufacturing and distribution of generic drugs. With its strong presence in the Japanese market, Nichi-Iko serves a significant role in providing affordable healthcare solutions to the local population. While its primary presence is in Japan, Nichi-Iko also has a global presence through strategic collaborations and partnerships to expand its reach and contribute to the global pharmaceutical industry.

What significant milestones has the company Nichi-Iko Pharmaceutical Co achieved?

Nichi-Iko Pharmaceutical Co Ltd, a leading company in the pharmaceutical industry, has achieved several significant milestones. Over the years, the company has successfully expanded its market presence and product portfolio. It has established itself as a key player in the generic pharmaceuticals sector, offering high-quality and affordable generic drugs to the global market. Nichi-Iko Pharmaceutical Co Ltd has also achieved noteworthy growth through strategic collaborations and acquisitions, enhancing its research capabilities and market reach. These achievements have catapulted the company's reputation and positioned it as an innovative and reliable provider of pharmaceutical solutions worldwide.

What is the history and background of the company Nichi-Iko Pharmaceutical Co?

Nichi-Iko Pharmaceutical Co Ltd, established in 1965, is a leading Japanese pharmaceutical company specializing in generic drugs. With its headquarters in Toyama, Japan, Nichi-Iko has a rich history of over 55 years in the industry. The company focuses on research and development, production, and sales of high-quality, affordable medications. Nichi-Iko aims to contribute towards better healthcare by providing accessible treatment options to patients worldwide. Over the years, Nichi-Iko has expanded its global presence through strategic partnerships and acquisitions, strengthening its position as a trusted provider of generic pharmaceuticals. Today, the company continues to innovate and drive advancements in the pharmaceutical field, forging a path towards a healthier future.

Who are the main competitors of Nichi-Iko Pharmaceutical Co in the market?

The main competitors of Nichi-Iko Pharmaceutical Co Ltd in the market include Towa Pharmaceutical Co Ltd, Sawai Pharmaceutical Co Ltd, and Eisai Co Ltd. These companies are recognized players in the pharmaceutical industry and pose notable competition to Nichi-Iko Pharmaceutical Co Ltd. Their presence and product offerings contribute to a competitive landscape within the market.

In which industries is Nichi-Iko Pharmaceutical Co primarily active?

Nichi-Iko Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Nichi-Iko Pharmaceutical Co?

The business model of Nichi-Iko Pharmaceutical Co Ltd focuses on the development, manufacturing, and sales of generic pharmaceutical products. As one of Japan's leading generic drug manufacturers, Nichi-Iko aims to provide affordable and high-quality medications to a wide range of patients. The company places great emphasis on research and development, ensuring the constant improvement and expansion of their product portfolio. Through strategic partnerships and acquisitions, Nichi-Iko continues to strengthen its position in the global pharmaceutical market, while maintaining a strong commitment to meeting the healthcare needs of individuals worldwide.

What is the P/E ratio of Nichi-Iko Pharmaceutical Co 2024?

The Nichi-Iko Pharmaceutical Co P/E ratio is -0.02.

What is the P/S ratio of Nichi-Iko Pharmaceutical Co 2024?

The Nichi-Iko Pharmaceutical Co P/S ratio is 0.01.

What is the AlleAktien quality score of Nichi-Iko Pharmaceutical Co?

The AlleAktien quality score for Nichi-Iko Pharmaceutical Co is 2/10.

What is the revenue of Nichi-Iko Pharmaceutical Co 2024?

The expected Nichi-Iko Pharmaceutical Co revenue is 201.8 B JPY.

How high is the profit of Nichi-Iko Pharmaceutical Co 2024?

The expected Nichi-Iko Pharmaceutical Co profit is -109.65 B JPY.

What is the business model of Nichi-Iko Pharmaceutical Co

Nichi-Iko Pharmaceutical Co Ltd is a Japanese pharmaceutical company that focuses on the manufacturing and distribution of pharmaceutical products. The company's business model is oriented towards the development, production, and marketing of generics. These medications are copies of well-known original preparations and are typically offered at a lower price. In recent years, the company has become one of the largest generic manufacturers in Japan through several acquisitions and collaborations. It also operates in the international market, including in the USA, Europe, Australia, and China. Nichi-Iko employs over 6,000 employees and operates in four main business areas: generics, biosimilars, innovative drugs, and contract manufacturing. Each of these areas has its own objectives and strategies to drive the company's growth. Generics The core business area of Nichi-Iko is the production of generics. The company offers a wide range of generic drugs used in various therapy areas such as cardiovascular diseases, gastroenterology, oncology, neurology, infectious diseases, and diabetes. Biosimilars Another important business area of Nichi-Iko is the manufacturing of biosimilars. These medications are biologics that have a similar structure and effect as originals. Nichi-Iko specializes in the development and production of biosimilars and offers them as a cost-effective alternative to expensive original preparations. Innovative drugs In addition to generics and biosimilars, Nichi-Iko also conducts research and development of innovative drugs. The company is working on the development of novel therapies for rare diseases and chronic conditions. The company's hope is to gain a competitive advantage over competitors with these products. Contract manufacturing Nichi-Iko also offers contract manufacturing (CMO) services. This includes the production of drugs for other pharmaceutical companies that do not have the capacity or technologies to manufacture them themselves. This business area has become an important driver of growth for the company. Products In addition to generics and biosimilars, Nichi-Iko offers a wide range of medications that can be used to treat various diseases. These include, among others, blood pressure-lowering medications, digestive disorders, antibiotics, painkillers, and cancer medications. The company also specializes in the production of medications for endocrinology, including drugs for the treatment of diabetes, thyroid, and adrenal gland problems. Conclusion Overall, Nichi-Iko is an innovative pharmaceutical company that specializes in the development and production of generics. Through acquisitions and collaborations, the company has become a significant player in the pharmaceutical industry and provides its products in various markets worldwide. The research and development activities of Nichi-Iko make the future of the company promising.

What is the Nichi-Iko Pharmaceutical Co dividend?

Nichi-Iko Pharmaceutical Co pays a dividend of 0 JPY distributed over payouts per year.

How often does Nichi-Iko Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Nichi-Iko Pharmaceutical Co or the company does not pay out a dividend.

What is the Nichi-Iko Pharmaceutical Co ISIN?

The ISIN of Nichi-Iko Pharmaceutical Co is JP3687200000.

What is the Nichi-Iko Pharmaceutical Co WKN?

The WKN of Nichi-Iko Pharmaceutical Co is A0DQVE.

What is the Nichi-Iko Pharmaceutical Co ticker?

The ticker of Nichi-Iko Pharmaceutical Co is 4541.T.

How much dividend does Nichi-Iko Pharmaceutical Co pay?

Over the past 12 months, Nichi-Iko Pharmaceutical Co paid a dividend of 20 JPY . This corresponds to a dividend yield of about 57.14 %. For the coming 12 months, Nichi-Iko Pharmaceutical Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nichi-Iko Pharmaceutical Co?

The current dividend yield of Nichi-Iko Pharmaceutical Co is 57.14 %.

When does Nichi-Iko Pharmaceutical Co pay dividends?

Nichi-Iko Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of April, October, April, October.

How secure is the dividend of Nichi-Iko Pharmaceutical Co?

Nichi-Iko Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Nichi-Iko Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nichi-Iko Pharmaceutical Co located?

Nichi-Iko Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nichi-Iko Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nichi-Iko Pharmaceutical Co from 12/1/2021 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 9/29/2021.

When did Nichi-Iko Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2021.

What was the dividend of Nichi-Iko Pharmaceutical Co in the year 2023?

In the year 2023, Nichi-Iko Pharmaceutical Co distributed 0 JPY as dividends.

In which currency does Nichi-Iko Pharmaceutical Co pay out the dividend?

The dividends of Nichi-Iko Pharmaceutical Co are distributed in JPY.

All fundamentals about Nichi-Iko Pharmaceutical Co

Our stock analysis for Nichi-Iko Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nichi-Iko Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.